- Jeito[1] reaffirms its commitment by participating in the IPO, following its significant investment in Odyssey’s recent oversubscribed $213 million series D financing round
- This renewed support underscores the company’s innovation potential for patients with autoimmune disease, an area of high unmet need
Paris, May 12th, 2026 – Jeito Capital, a leading global independent private equity firm dedicated to biopharma, today announced Jeito II fund’s participation in the upsized IPO of its portfolio company Odyssey (“Odyssey”) which raised a total of $304 million[2] at an IPO price of $18.00 per share. The company began trading under the ticker NASDAQ: ODTX on May 8.
This renewed investment follows Jeito’s[1] significant participation in Odyssey’s $213 million Series D financing round in September 2025.
Odyssey Therapeutics is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology. Since its founding in 2021, Odyssey has built a portfolio of completely internally discovered and developed medicines with its first program advancing through multiple clinical milestones.
Odyssey intends to use the net proceeds from the offering to advance the clinical development of OD-001[3], Odyssey’s most advanced product candidate, through the next major data readouts coming from OD-001 phase 2a combination trial and phase 2b monotherapy trial in ulcerative colitis. This will also support the advancement of a second program targeting SLC15A4 (OD-002)[4] through Phase 1/2a clinical trials as well as fund the rest of the pipeline and run the business, including additional research on other current or future drug programs, supporting technologies, and general operating costs.
[1] Jeito through Jeito II SLP
[2] It includes an upsized initial public offering of 15,500,000 shares of its common stock at an initial public offering price of $18.00 per share and a concurrent private placement: sale of 1,388,889 shares of common stock to an affiliate of TPG Life Sciences Innovations, at the initial public offering price of $18.00 per share
[3] OD-001, is an oral small-molecule RIPK2 scaffolding inhibitor in development for Inflammatory Bowel Disease (IBD), including ulcerative colitis (UC) and Crohn’s disease
[4] SLC15A4 (OD-002) is an oral small molecule SLC15A4 inhibitor in development for multiple inflammatory or interferon-mediated diseases, including lupus, Sjögren’s syndrome, dermatomyositis, systemic sclerosis, nephropathies, and other B cell-mediated diseases
Ksenija Pavletic, General Partner & Chief Commercial Officer of Jeito Capital, and also a Board member at Odyssey, said: « I would like to congratulate Gary D. Glick, PhD, and the management team on the success of the IPO, which fully reflects the unprecedented potential of Odyssey’s programs in a field of autoimmune diseases where patient needs remain highly unsatisfied. This potential reinforces our commitment to the company and the exceptional team. We look forward to supporting the company to accelerate its development for the benefit of patients. »
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Jeito Capital
Jeito Capital is a global leading private equity firm with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. With €1.6 billion in assets under management, Jeito empowers and supports managers through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access globally, especially in Europe and the United States. Jeito has built a diversified portfolio of clinical biopharmas with cutting-edge innovations addressing high unmet needs. Jeito Capital is based in Paris with a presence in Europe and the United States.
For more information, please visit www.jeito.life or follow us on LinkedIn.
About Odyssey Therapeutics
Odyssey Therapeutics is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology. Since its founding in 2021, Odyssey has built a portfolio of completely internally discovered and developed medicines with its first program advancing through multiple clinical milestones. The portfolio leverages the scientific expertise of its team of experienced drug hunters and a comprehensive suite of tools to efficiently advance product candidates that the company believes have the potential to induce deep and durable remission for patients across several inflammatory diseases with unmet need.
For more information, please contact:
Jeito Capital
Communication
media@jeito.life
Stéphanie Elbaz
Tel.: +33 6 46 05 08 07
H/Advisors Maitland
Finlay Donaldson
finlay.donaldson@h-advisors.global
Tel.: +44 (0) 7341 788 066